Sunrest Lifescience
SUNREST NSE
Sunrest Lifescience
HealthcareNSE: SUNREST Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹63.85 Cr
Volatility
Moderate
P/E Ratio
4
EBITDA
₹4.82 Cr
Return on Equity
12.36%
Debt to Equity
0.85
Book Value
₹41.3
EPS
₹0.53
52W High
₹54
52W Low
₹29.55
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Stock is trading at 0.80 times its book value
- Debtor days have improved from 282 to 167 days.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 167 days.
Growth Rate
Revenue Growth
0.48% lower than
3Y
Net Income Growth
54.5%
Cash Flow Change
110% higher than
3Y
ROE
677% higher than
3Y
ROCE
207% higher than
3Y
EBITDA Margin (Avg.)
59.93% lower than
3Y
Quarterly Results
| Particulars | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 15.39 | 34.01 | 36.82 |
| Expenses | 14.48 | 31.56 | 30.07 |
| Operating Profit | 0.91 | 2.45 | 6.75 |
| OPM % | 5.91% | 7.2% | 18.33% |
| Other Income | 0 | 0 | 2.51 |
| Interest | 0.12 | 0.72 | 0.7 |
| Depreciation | 0.01 | 0.68 | 0.51 |
| PBT | 0.78 | 1.05 | 8.05 |
| Tax % | 24.36% | 37.14% | 18.51% |
| Net Profit | 0.58 | 0.66 | 6.57 |
| EPS in Rs | 1.35 | 0.79 | 7.88 |
Profit & Loss
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 33.41 | 70.83 |
| Expenses | 30.38 | 60.62 |
| Operating Profit | 3.03 | 10.21 |
| OPM % | 9.07% | 14.41% |
| Other Income | 0 | 2.51 |
| Interest | 0.31 | 1.42 |
| Depreciation | 0.1 | 1.19 |
| PBT | 2.62 | 10.11 |
| Tax % | 23.28% | 20.87% |
| Net Profit | 2.02 | 8 |
| EPS in Rs | 4.68 | 9.6 |
| Div. Payout % | 0% | 0% |
Balance Sheet
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity Capital | 4.29 | 4.29 |
| Reserves | 12.02 | 16.14 |
| Borrowings | 12.05 | 17.46 |
| Other Liabilities | 30.29 | 33.52 |
| Total Liabilities | 58.65 | 71.41 |
| Fixed Assets | 4.36 | 8.55 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 54.29 | 62.86 |
| Total Assets | 58.65 | 71.41 |
Cash Flow
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | 2.92 | -0.05 |
| Investing | -1.15 | -2.91 |
| Financing | -0.33 | 3.99 |
| Net Cash Flow | 1.45 | 1.03 |
| Free Cash Flow | 1.76 | -2.76 |
| CFO/OP | 112 | 14 |
Ratios
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Debtor Days | 397 | 167 |
| Inventory Days | 175 | 141 |
| Days Payable | 417 | 173 |
| Cash Conversion Cycle | 156 | 135 |
| Working Capital Days | 228 | 156 |
| ROCE % | — | 28.55% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sunrest Lifescience insights
29 extracted metrics + investor summaries across FY25–FY26.
Documents
1
Outcome of Board Meeting
11 Sep - Board dissolved rights issue opened August 18 and extended to September 11, 2026; funds will be unblocked. 11 Sep - Board dissolved rights issue opened August 18 and extended to September 11, 2026; funds will be unblocked.
2
Shareholders meeting
7 Sep - Sunrest Lifescience held its 9th AGM on 7 Sep 2026; approved financials, director reappointments and related-party transactions. 7 Sep - Sunrest Lifescience held its 9th AGM on 7 Sep 2026; approved financials, director reappointments and related-party transactions.
3
Shareholders meeting
7 Sep - Sunrest Lifescience filed voting results and scrutinizer report for its 9th AGM held on 7 September 2026. 7 Sep - Sunrest Lifescience filed voting results and scrutinizer report for its 9th AGM held on 7 September 2026.
4
Copy of Newspaper Publication
3 Sep - Newspaper publications disclose rights issue closure date extended from September 2, 2026 to September 11, 2026. 3 Sep - Newspaper publications disclose rights issue closure date extended from September 2, 2026 to September 11, 2026.
5
Rights Issue
2 Sep - Sunrest Lifescience extended its rights issue closing date by 9 days to September 11, 2026. 2 Sep - Sunrest Lifescience extended its rights issue closing date by 9 days to September 11, 2026.
Frequently Asked Questions about Sunrest Lifescience
What does Sunrest Lifescience Ltd do?
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
Where is Sunrest Lifescience Ltd (SUNREST) listed?
Sunrest Lifescience Ltd trades as SUNREST on the NSE.
Which sector does Sunrest Lifescience Ltd belong to?
Sunrest Lifescience Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Sunrest Lifescience Ltd?
Sunrest Lifescience Ltd has a market capitalisation of ₹63.85 Cr, which places it in the Small Cap band.
What is the PE ratio of Sunrest Lifescience Ltd?
Sunrest Lifescience Ltd trades at a PE ratio of 4.00, on earnings per share of ₹0.53, against a book value of ₹41.3 per share.
What is the 52-week high and low of Sunrest Lifescience Ltd?
Over the last 52 weeks Sunrest Lifescience Ltd has traded between ₹29.55 and ₹54.
What is the Return on Equity (ROE) of Sunrest Lifescience Ltd?
Sunrest Lifescience Ltd reported a return on equity of 12.36%. Its debt-to-equity ratio is 0.85.
Company Information
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUNREST.md for Sunrest Lifescience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.